Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Notice of Half Year Results
2 December 2022 - Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, will report its half year results for the six months ended 30 September 2022 on Thursday, 8 December 2022.
Dr Huw Jones, Chief Executive Officer, and Richard Moulson, Chief Financial Officer, will present the results via the Investor Meet Company platform on 8 December at 14:00 GMT. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Evgen Pharma plc here. Investors who already follow Evgen on the Investor Meet Company platform will automatically be invited. The presentation and recording will be available on the Company's website after the event here.
-Ends-
Enquiries:
| Evgen Pharma plc | +44 1625 466591 |
| FinnCap (Nominated Advisor and Broker) | +44 20 7220 0500 |
| Instinctif Partners Melanie Toyne-Sewell / Rozi Morris / Agnes Stephens / Adam Loudon | +44 207 457 2020 |
Notes to Editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer. In September 2021 the FDA granted Orphan Drug status to SFX-01 in malignant glioma.
The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and AsiaPac as part of the continuing strategy to build the data set of safety and efficacy around the compound. With respect to non-core area, Evgen signed an out-licensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex® technology. Evgen also has a licensing deal with STALICLA SA in neurodevelopmental disorders and schizophrenia.
The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.